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The transcription factor Pax6, which belongs to the paired 
box-containing gene family, regulates developmental pro-
cesses, especially in the eyes, central nervous tissues and 
craniofacial structures. However, the role of Pax6 in bone 
has never been studied exclusively. Here we report that 
Pax6 is expressed at both the mRNA and protein level in 
the calvaria and long bones of adult mice as well as osteo-
cyte-like MLOY4 cells and suppresses the canonical Wnt 
signaling pathway. Moreover, the expression levels of 
Pax6 were much higher in the calvaria than the long bones, 
and Pax6 was also expressed at E16 to E18 in both the 
calvaria and long bones. Knockdown of Pax6 in MLOY4 
cells did not affect cell proliferation or survival; however, 
the expression of Sost, an osteocyte marker gene, was 
significantly decreased. In addition, the overexpression of 
Pax6 suppressed the canonical Wnt signaling pathway by 
enhancing the expression of Sost. Furthermore, we also 
demonstrated that Pax6 binds to the Sost promoter and 
that stimulation of Sost transcription by Pax6 was de-
pendent on a specific Pax6-binding sequence within the 
promoter. In conclusion, the results of the present study 
suggest that Pax6 is expressed in bone and may play an 
important role in osteocyte differentiation by controlling 
canonical Wnt signaling. 
 
 
INTRODUCTION 
 
Osteocytes are derived from matrix-producing osteoblasts. 
Osteoblasts move along the bone surface before localizing to a 
targeted, pre-determined location where they become embed-
ded in the newly forming osteoid bone matrix. Once embedded, 
their dendritic processes can extend and retract, and the cell 
bodies are able to undulate within their lacunae (Dallas and 
Bonewald, 2010). Osteocytes play multifunctional roles as 
mechanosensors, re-gulators of mineral homeostasis and co-
ordinators of bone remodeling processes carried out by os-
teoblasts and osteoclasts (Lanyon, 1993). Osteoblasts differen-
tiate into osteocytes in a series of several stages (Franz-
Odendaal et al., 2006). However, the molecular and cellular 
mechanisms governing osteoblast and osteocyte differentiation 
are largely unknown.  
Sclerostin, the product of the Sost gene, was previously iden-
tified as an important negative regulator of bone formation in 
two rare bone sclerosing dysplasias, Sclerosteosis and Van 
Buchem disease (van Bezooijen et al., 2004). Sclerostin is a 
secretory glycoprotein that plays a key role in the regulation of 
bone formation through Wnt signaling (Semenov, 2005). More-
over, expression and secretion of sclerostin have been reported 
in terminally differentiated osteocytes (van Bezooijen et al., 
2009). In our study, transcription factors that were upregulated 
with Sost were analyzed using gene expression omnibus 
(GEO) analysis (in silico analysis) (Barrett et al., 2007). Pax6 
was identified as one of the transcription factors that were 
upregulated with the Sost gene in GEO analysis.  
Pax6 belongs to the paired box-containing gene family, and 
acts as a transcription factor regulating developmental proc-
esses (Walther and Gruss, 1991). Pax6 is also known to regu-
late the development of eyes, central nervous tissues and cra-
niofacial structures (Hogan et al., 1988; Kaufman et al., 1995; 
Stoykova et al., 1996; Theiler et al., 1978). Pax6, encoded by 
the Pax6 gene, contains two DNA-binding domains, the paired 
domain (PD) and the homeo-domain (HD), as well as a trans-
activation domain. In vertebra-tes, several isoforms of Pax6 are 
encoded by the Pax6 gene (Carriere et al., 1995; Jaworski et al., 
1997; Kim and Lauderdale, 2006). Two major isoforms are pro-
duced by the Pax6 gene by alternative splicing, Pax6 (+5a) and 
Pax6(-5a). Pax6(+5a) differs from Pax6(-5a) by the presence of 
an exon 5a-encoded 14 amino acid insertion in its PD. These 
two isoforms demonstrate distinct DNA-binding properties to 
the promoters of their downstream target proteins (Carriere et 
al., 1995; Jaworski et al., 1997; Tang et al., 1998; Walther and 
Gruss, 1991; Zhang et al., 2001). Pax6(-5a) has been shown to 
influence both cell proliferation and neuronal differentiation,
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Table 1. RT-PCR and real-time PCR primers 
Target name Forward primer Reverse primer 
RT-PCR 
Pax6 
Pax6 isoform 
 
5′-AGTTCTTCGCAACCTGGCTA-3′ 
5′-TGCGACATTTCCCGAATT-3′ 
 
5′-GAGCCT CAATCTGCTCTTGG-3′ 
5′-TCTGTCTCGGATTTCCCAAG-3′ 
Sost 5′-CCTATGACGCCAAAGATGTG-3′ 5′-GTTGTGGAAGCGGGTGAG-3′ 
E11 5′-AGTGTTGTTCTGGGTTTTGG-3′ 5′-GATTCCGACCAGGGTCACTA-3′ 
DMP1 5′-AGTGAGGAGGACAGCCTGAA-3′ 5′-TCCCTGTGGAGTTGCTCTCT-3′ 
β-actin 
Real-time PCR 
Gapdh  
Sost  
5′-TTCAACACCCCAGCCATGT-3′ 
 
5′-AATGTGTCCGTCGTGGATCTG-3′ 
5′-TCCTGAGAACAACCAGACCA-3′ 
5′-TGTGGTACGACCAGAGGCATAC-3′ 
 
5′-CAACCTGGTCCTCAGTGTAGC-3′ 
5′-GCAGCTGTACTCGGACACATC-3′ 
 
 
while Pax6(+5a) has only been shown to affect proliferation 
(Berger et al., 2007; Cillo et al., 1991; Haubst et al., 2004; 
Lauderdale et al., 2000). The canonical Wnt signaling pathway 
is involved in many developmental processes (Wodarz and 
Nusse, 1998). Moreover, Pax6 is known to play an important 
role in lens morphogenesis through the inhibition of canonical 
Wnt/β-catenin signaling in the lens surface ectoderm. Previ-
ously, Pax6 was shown to regulate the expression of negative 
regulators of the Wnt signaling pathway, such as secreted 
frizzeled-related protein1 (sfrp1) and secreted frizzeled-related 
protein 2 (sfrp2) (Machon and Nusse, 2010). Although the ca-
nonical Wnt signaling is known to play a role in deciding the 
fate of osteoblast lineage cells, as well as in the regulation of 
bone mass and homeostasis (Johnson et al., 2004), the role of 
Pax6 in bone has never been reported.  
In the present study, we experimentally showed the expres-
sion of Pax6 in bone tissues and MLOY4 established osteo-
cyte-like cell lines, the regulation of the Sost gene by Pax6, and 
its role in inhibiting Wnt signaling. 
 
MATERIALS AND METHODS 
 
Animal study 
Embryos used in this study were obtained from time-mated 
adult imprinting control region (ICR) pregnant mice. Embryonic 
day 0 (E0) was designated as the day on which vaginal plugs 
were confirmed. Embryos at E16, E18 were used in this study. 
 
Cell culture 
Osteocyte-like MLOY4 cells were cultured as previously de-
scribed (Kato et al., 1997; Ma et al., 2012). Mouse primary 
calvarial cells were prepared from the calvaria of neonatal mice 
as previously described (Park et al., 2007). Mouse primary cal-
varial cells and mouse pre-osteoblast MC3T3-E1 cells were 
cultured as described elsewhere (Park et al., 2007). To induce 
osteoblast differentiation, MC3T3-E1 cells were supplemented 
with α-MEM containing 50 μg/ml ascorbic acid (Sigma, USA) 
and 10 mM β-glycerophos-phate (Sigma, USA). The differentia-
tion medium was replaced every two days.  
 
Alkaline phosphatase (ALP) staining  
To study the osteoblast differentiation, ALP staining was done 
using ALP staining kit (Sigma, USA) according to the manufac-
turer’s protocol.  
 
RNA analysis 
Total RNA isolation and cDNA synthesis were performed as 
previously described (Kato et al., 2007). In total, 1 μl of cDNA 
was used as the template for PCR amplification of β-Actin, 
Pax6, Pax6 isoform, Sost, DMP1 and E11 along with 10 pmole 
of primer and Go-Taq DNA polymerase (Promega, USA). Am-
plification was carried out at 95°C for initial denaturation, fol-
lowed by appropriate cycles at 95°C for 30 s (denaturation), 
55°C (for β-Actin, Pax6, Pax6 isoform and E11) or 57°C (for 
DMP1 and Sost) for 30 s (annealing) and 72°C for 30 s (polym-
erization). Pax6 isoform primers were designed in exon5a of 
Pax6. Amplified products were resolved on a 1.7% agarose gel. 
Quantitative real-time PCR was performed for the quantitation 
of Pax6, Sost, E11 and DMP1 with the Applied Biosystems 
Real-time PCR system with SYBR green mix (Promega, USA) 
as a double-stranded DNA-specific binding dye. The primers 
used in this study are listed in Table 1. We used the same 
primers to amplify Pax6, E11 and DMP1 for both real-time PCR 
and RT-PCR. 
 
Plasmid constructs and transfection 
To clone Pax6(+5a) and Pax6(-5a), we amplified these two 
isoforms using MLOY4 cDNA with the following primer se-
quences: forward sequence, 5′-GCGGTGAGCAG ATGTGTG-
3′, and reverse sequence, 5′-TCTCCTTCTCTCTTTACTGTA 
ATC-3′. The PCR products were cloned into the T&A cloning 
vector (RBC Life Sciences, Real Biotech Corporation, Taiwan) 
and subcloned into a pcDNA3.1 mammalian expression vector 
(Invitrogen, USA) after digestion with HindIII restriction enzyme 
to generate expression constructs [i.e., pcDNA3.1-Pax6(+5a) 
and pcDNA3.1-Pax6(-5a)]. Cells were then seeded in 6-well 
plates and transfected with 0.8 μg of pax6 plasmid at 70-80% 
confluency using Lipofectamine Plus™ reagent (Invitrogen, 
USA). At 48 h after transfection, the cells were processed to 
determine mRNA and protein expression levels of Pax6 and 
other osteocyte marker genes. 
 
Sost reporter plasmid construction 
The 1,811 bp of the human Sost promoter (spanning nucleo-
tides -1,956 to -145 bp of the Sost gene locus relative to the 
position (+1) of the initiation methionine for the Sost open read-
ing frame) was amplified from liver cells with the following 
primer sequences forward sequence (5′-TCTCCCCCGGGTG 
TGGATCATTTAGAGGTTCA AG-3′) and reverse sequence 
(5′-GCCCTAGATCTCCCAAAGACTTCTCCTCTAGCT C-3′). 
The promoter was cloned into a pGL3-basic luciferase reporter 
vector after digestion of the PCR product with SmaI and BglII to 
construct the pGL3-Sost promoter (wt) plasmid. The primers 
used to generate mutations in the transcription factor binding 
site were as follows (mutated nucleotides are indicated in bold 
letters): forward-5′-CTCTGGGTCACCTGGAAGTACAAACAG 
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CAATTTGGAAGTTTGC-3′; and reverse-5′-GCAAACTTCCA 
AATTGCTGTTTGTACTTCCAGGTGACCCAGAG-3′. A pGL3-
Sost promoter (mut) plasmid was generated by site direct muta- 
genesis using Expand long range dNTPack enzyme (Roche, 
Germany) utilizing the pGL3-Sost promoter (wt) plasmid as a 
template. 
 
Transfection of cells with small interfering RNA 
Control siRNA (sc-37007; Santa Cruz Biotechnology Inc., USA) 
and Pax6 siRNA (sc-36196; Santa Cruz Biotechnology Inc., 
USA) were used in this study. MLOY4 cells were seeded into 
12-well plates and transfected with 50 pmoles of control siRNA 
or Pax6 siRNA using Lipofectamine RNAiMax reagent (Invitro-
gen, USA) according to the manufacturer’s protocol.  
 
Cell proliferation and Cell number assay 
MLOY4 cells were cultured in 12-well plates and transfected 
with Pax6 siRNA. After 60 h, cell proliferation levels were de-
termined using a cell counting kit-8 (Dojindo Molecular Tech-
nologies Inc., Japan) according to the manufacturer’s instruc-
tions. The cell number (viability) was determined by measuring 
lactate dehydrogenase (LDH) activity with a Cytotox 96 nonra-
dioactive cytotoxicity assay (Promega, USA). MLOY4 cells in 
12-well plates were transfected with 0.6 μg of pcDNA3.1 empty 
vector, pcDNA3.1-Pax6(-5a) or pcDNA3.1-Pax6(+5a) plasmids 
using Lipofectamine Plus™ reagent. After 48 h, the effects of 
the Pax6 expression plasmids on cell proliferation and viability 
were studied. 
 
Western blot analysis 
Tissue samples and cell lysate samples were loaded and sepa-
rated on 12% sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) gels and transferred to polyvinylidene 
difluoride (PVDF) membranes (Millipore, USA). The membrane 
was incubated with anti-Pax6 antibody (sc-53108; Santa Cruz 
Biotechnology Inc., USA) and anti-β-Actin antibody (sc-8432; 
Santa Cruz Biotechnology Inc., USA). After washing, the mem-
brane was incubated with secondary antibody for 1 h. Immuno-
reactive proteins on the membrane were visualized with en-
hanced chemiluminescence (ECL) detection kits (Santa Cruz 
Biotechnology, USA). 
 
Preparation of Wnt-3a conditioned medium 
Wnt-3a conditioned medium was obtained from established L-
Wnt-3a stable cell lines (CRL-2647), which were purchased 
from ATCC (ATCC, USA). 
 
Chromatin immunoprecipitation (Chip) assay 
The Sost promoter (~2 kb) was analyzed for Pax6 binding ele-
ments using r-vista software analysis, which showed the puta-
tive Pax6 binding site (GGGAGTGCCAG) on the Sost promoter. 
This sequence was found to be a conserved region between 
mice and humans. For Chip assay, MLOY4 cells were cross-
linked with 1% formaldehyde for 10 min at room temperature. 
Cross linking was stopped by using 0.125 M glycine, followed 
by washing with ice-cold PBS. After cell lysis, chromatin ex-
tracts were prepared and fragmented by sonication on ice. 
Protein A/G beads (Santa Cruz Biotechnology Inc., USA) were 
equilibrated with RIPA buffer and added to 50 μg of chromatin 
extract for preclearing. DNA-protein-antibody complexes were 
prepared using anti-Pax6 antibody following the Chip protocol 
(Abcam, USA) with minor modifications. After precipitation of 
the chromatin, bound DNA was resuspended in water and used 
as a template for PCR using Sost Chip primers, forward 5′-
TCTGAAAACCACAGCCTGAC-3′; and reverse 5′-GTTTCCT 
CACCCTC CTCCTC-3′ to amplify the conserved Pax6 binding 
site of mouse Sost promoter (-317 to -87 bp upstream to trans-
lation initiation site). For the control, Chip primers were de-
signed in the other region of mouse Sost promoter (-1,910 to   
-1,676 bp). The control Chip primers are as follows; forward 5′-
TCTCCCAAGTCTGGAGCAAT-3′; and reverse 5′-GCAGACA 
GAAGTCCCCTCAG -3′.  
 
Luciferase reporter assay for monitoring Sost promoter  
activity and Wnt signaling 
To study the role of Pax6 on Sost promoter activity and Wnt 
signaling, MLOY4 cells were plated in 24-well and 12-well 
plates at a density of 55,000 cells/well and 1.1 × 105 cells/well, 
respectively, and subsequently co-transfected using Lipofec-
tamine Plus™ reagent with the indicated combinations of ex-
pression and reporter plasmids. In the Wnt signaling study, the 
Super TOPFlash plasmid (S-Top) (Clontech, USA) was co-
transfected with Pax6 expression plasmids, and 24 h after 
transfection, the cells were treated with 100 μl of Wnt-3a condi-
tioned medium. At 48 h after transfection, cell lysates were pre-
pared, and luciferase assays were performed using the Dual-
Luciferase Reporter Assay system (Promega, USA) according 
to the manufacturer’s protocol. Assays were normalized for 
transfection efficiency by co-transfecting with 2.5 ng of pRL-tk 
renilla luciferase reporter plasmid. 
 
Induction of Pax6 expression by Wnt-3a treatment 
MLOY4 cells were seeded in 12-well plates and treated with 
100 μl of Wnt-3a conditioned media, and Pax6 and Sost mRNA 
expressions were measured at different time intervals. 
 
Immunohistochemistry and HE staining 
For immunohistochemical staining, mandibles from mice at 
each stage were fixed with 4% paraformaldehyde in 0.01 M 
phosphate-buffered saline (PBS, pH 7.4) overnight at 4°C and 
demineralized with 10% ethylenediaminetetraacetic acid (pH 
7.4) for 2 wks at 4°C. After being embedded in paraffin, these 
samples were sectioned to a thickness of 6 μm. Sections were 
then blocked in 3% hydrogen peroxide for 15 min. The tissue 
sections were boiled in 10 mM citrate buffer (pH 6.0) for 10 min 
and cooled at room temperature for 20 min. The immu-
nostained sections were then counterstained with hematoxylin. 
These sections were used for immunohistochemistry. Speci-
mens were incubated with a primary mouse monoclonal anti-
body against Pax6 (Santa Cruz) at 4°C overnight. After wash-
ing with PBS, the specimens were incubated with a secondary 
antibody at room temperature. The specimens were visualized 
using a 3,3′-diaminobenzidine (DAB) reagent kit (Zymed labo-
ratories, USA). 
 
Statistics 
Statistical significance was evaluated using Sigma Plot10 soft-
ware. The results were calculated and expressed as the mean 
± standard deviation (SD). Statistical significance was deter-
mined using Student’s t-test. P-values ≤ 0.05 were considered 
to be statistically significant. 
 
RESULTS 
 
Endogenous expression of Pax6 in various types of bone  
cells and tissues 
To study the endogenous expression of Pax6 in bone cells and 
tissues, we investigated the expression of Pax6 in primary cal- 
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varial cells, MC3T3E1 preosteoblast cells and osteocyte-like 
MLOY4 cells at the mRNA and protein level. Pax6 mRNA was 
expressed at high levels in MLOY4 cells compared to those in 
primary calvarial cells and MC3T3-E1 cells (Figs. 1A and 1B). 
Alternative splicing of Pax6 is known to result in two major Pax6 
isoforms, both of which we detected in MLOY4 cells (Fig. 1B). 
In addition, our Western blot analysis demonstrated the in vivo 
expression pattern of Pax6 in calvaria and long bone tissues of 
adult mice (Fig. 1C). Pax6 expression at the protein level in 
MLOY4 cell lysates was confirmed by loading Pax6(-5a)- and 
Pax6(+5a)- overexpressing cell lysates. The Pax6(-5a) isoform 
was found in MLOY4 cells (Fig. 1D). To examine the expres-
sion of Pax6 during osteoblast differentiation, MC3T3-E1 cells 
were differentiated using osteoblast differentiation media. Dif-
ferentiation of osteoblast cells was shown by ALP staining (Fig. 
1E). The expression of Pax6 was gradually increased as the 
differentiation progressed (Fig. 1F). Immunohistochemical stud-
ies showed the expression of Pax6 in osteoblasts and osteo-
cytes in parietal bone region of calvaria sections at E16 and 
E18 embryonic stages. Whereas the long bone sections of E16 
and E18 showed expression of Pax6 in both osteoblasts and 
osteocytes. Calvaria at E16 and E18 stages showed compara-
tively higher expression than long bone (Fig. 2). 
 
Effect of Pax6 on Wnt inhibitor Sost and other osteocyte  
markers 
We then studied the effect of Pax6 on osteocyte marker genes 
via the knockdown or overexpression of Pax6 in MLOY4 cells. 
The gel images and semi-quantitative RT-PCR and real-time 
PCR data showed a significant knockdown of Pax6 (Figs. 3A 
and 3B). Knockdown of Pax6 increased the expression of E11 
and DMP1 and decreased the expression of Sost (Figs. 3A and 
3C). In contrast, the overexpression of Pax6(-5a) and Pax6 
(+5a) in MLOY4 cells resulted in an increase in the expression 
of Sost, which is a mature osteocyte marker gene; meanwhile, 
there were no changes in the other marker genes, as observed 
with RT-PCR and real-time PCR (Figs. 3D-3G). Together, these 
results suggest that osteocyte-specific expression of Pax6 
might be involved in the transition of pre-osteocytes to mature 
osteocytes and may also play an important role in inhibiting Wnt 
signaling through enhanced Sost expression. In addition to 
these results, we studied the effect of Pax6 on the proliferation 
Fig. 1. Endogenous expression of Pax6 in bone
cells and tissues. (A) RT-PCR analysis of Pax6
expression in mouse primary calvarial cells, MC3T3-
E1 pre-osteoblast cells and osteocyte-like MLOY4
cells. (B) RT-PCR analysis of the endogenous
expression of the two major isoforms of Pax6
[Pax6(+5a) and Pax6(-5a)]. Their relative expres-
sions are shown in the bar graph [Pax6-5a (black
bar), Pax6+5a (gray bar)]. (C) Endogenous Pax6
expression in calvaria and long bone tissues was
analyzed with Western blotting and normalized to
beta-actin expression. (D) Endogenous expression
levels of Pax6 in MLOY4 lysates were compared
with the overexpression of Pax6(-5a) and Pax6
(+5a). (E) MC3T3-E1 cells differentiation was con-
firmed by ALP staining. (F) Pax6 expression was
increased after induction of MC3T3-E1 cells with
differentiation media. 
Fig. 2. Immunohistochemical analysis of endogenous Pax6
expression in the calvaria and long bone tissues at embryonic
stage 16 and 18. Brown color stained positive cells for Pax6 are
indicated by arrows in each embryonic stages. Osteoblasts are
indicated by red arrows, osteocytes are indicated by black ar-
rows. Scale bar = 50 µm. 
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and cell number (viability) of MLOY4 cells. We found that nei- 
ther knockdown nor overexpression of Pax6 in MLOY4 cells 
had a significant effect on proliferation or cell number (Figs. 3H-
3K).  
 
 
Effect of Pax6 on Sost promoter activity in MLOY4 cells 
From the Insilico analysis we found one Pax6 binding site on 
the Sost promoter (~2 kb) (Figs. 4A and 4B). This was further 
confirmed by Chip-PCR analysis. Pax6-bound chromatin was 
isolated from MLOY4 cells and immunoprecipitated with anti-
Pax6 antibody. The Pax6-bound DNA fragment shows amplify-
Fig. 3. The effects of Pax6 on osteocyte
marker genes and proliferation. The expres-
sion of osteocyte marker genes was ana-
lyzed with RT-PCR or real-time PCR. (A-C)
Effect of siPax6 on osteocyte marker genes.
RT-PCR and real-time PCR analysis showed
significantly decreased expression of Sost.
and increased expression of DMP-1 and E11
in siPax6 transfected cells compared to con-
trol siRNA transfected cells. (D-G) Effect of
Pax6 overexpression on osteocyte marker
genes. RT-PCR and real time PCR analysis
showed significantly increased expression of
Sost by Pax6 overexpression compared to
empty vector transfection. (H-I) Effect of si-
Pax6 on cell proliferation and cell number.
There is no effect on cell proliferation and cell
number in cells treated with siPax6 compared
to control siRNA. (J) Represents the effect of
overexpression of Pax6(+5a) or Pax6(-5a)
expression plasmids on cell proliferation com-
pared to empty vector transfection. (K) Re-
presents the effect of transient transfection of
Pax6 expression plasmids on cell number
compared to control vector. *Indicates a p-
value ≤ 0.05 relative to the control. 
Fig. 4. The binding of Pax6 to the 5′ up-
stream promoter region of Sost on Chip as-
say and the effect of Pax6 on Sost promoter
activity. (A) Sequence analysis of the 2 kb
upstream regulatory region of human Sost..
promoter (1 kb region shown here). Putative
Pax6 conserved binding site was represented
in bold. (B) The conserved Pax6 binding site.
(C) Chip PCR analysis in MLOY4 cells. PCR
amplification was performed by using Pax6
binding element region specific primers (up-
per panel) and negative control primers (lower
panel) as described in the “Materials and
Methods”. This result confirms the specificity
of Pax6 binding element on Sost. promoter.
(D) MLOY4 cells were transfected with the
indicated combinations of the wild type and
mutant Sost promoter and Pax6 expression
plasmids. After 48 h, the relative luciferase
activity was measured. *Indicates a p-value
≤ 0.05 relative to the control. 
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cation with specific primer set (Fig. 4C), whereas the control 
primers designed in the other region shows no amplification 
(Fig. 4C). This result confirmed the specificity of Pax6 binding 
site on the Sost promoter. Since we found that Pax6 regulates 
the expression of the Sost gene, we further investigated the 
possible mechanism of Pax6 on Sost expression. To confirm 
the regulatory mechanism, we cloned 1,811 bp of the human 
Sost promoter containing the Pax6-binding site (-1,956 to -145 
bp) into a pGL3-basic luciferase reporter vector, and evaluated 
the ability of this promoter fragment to drive luciferase expres-
sion in MLOY4 cells. Co-transfection of Pax6(+5a) or Pax6(-5a) 
plasmids with the wild type and mutant pGL3-Sost-promoter 
vectors led to a significant increase in promoter activity after 
overexpression of Pax6 in the wild type promoter and a de-
crease in activity in the mutant promoter in the presence of both 
isoforms of Pax6 (Fig. 4D). Since the Pax6 could not bind to the 
mutated region of the promoter, hence there was a significant 
decrease of reporter activity after overexpression of both forms 
of Pax6 compared to the wild type promoter (Fig. 4D). This 
result suggested that Pax6 regulates Sost expression by bind-
ing to its promoter region specifically. 
 
Effect of Wnt-3a on Pax6 mRNA expression in MLOY4 cells 
Sost is a negative regulator of Wnt signaling. Because Pax6 
regulates Sost expression, we investigated the effect of Wnt-3a 
on Pax6 mRNA expression in MLOY4 cells. Interestingly, we 
found that Wnt-3a stimulated the expression of Pax6 mRNA at 
different time points, which further stimulated the expression of 
Sost mRNA (Fig. 5A). In addition, we studied the effects of 
Pax6 on the S-Top reporter vector, which is driven by T-cell 
factor (TCF)/lymphoid enhancer factor (LEF)-binding elements 
and is responsive to Wnt signaling. However, the co-expression 
of the S-Top plasmid with Pax6 isoforms showed an inhibition 
of Wnt/β-catenin signaling in MLOY4 cells (Fig. 5B). These 
results suggested that Pax6 plays an important role in the inhi-
bition of Wnt signaling mediated by the Sost gene in MLOY4 
cells. Additionally, we found that Wnt-3a enhanced Pax6 ex-
pression. In turn, overexpression of Pax6 inhibited Wnt signal-
ing by increasing the expression of Sost, which is a potent in-
hibitor of Wnt signaling (Fig. 5C). 
 
 
 
DISCUSSION 
 
Canonical Wnt/β-catenin signaling plays important role in skele-
tal development, tissue regeneration and bone formation (Kri-
shnan et al., 2006). Postnatally, it also regulates bone homeo-
stasis and bone mass (Knothe et al., 2004). Sost encodes scle-
rostin, which is specifically expressed by osteocytes and acts 
through a network of osteocyte canaliculi to reach the surface 
of the bone (Poole et al., 2005; Weidauer et al., 2009). Scle-
rostin inhibits canonical Wnt signaling by binding to LRP5,6 (Li 
et al., 2005). 
In our GEO analysis, Pax6 was found to be a transcription 
factor that was upregulated with the Sost gene (data not 
shown). Pax6 acts as an important regulator in the develop-
ment of the eye and central nervous tissues (Stoykova et al., 
1996; Theiler et al., 1978). Pax6 is abundantly expressed in 
developing eyes, the forebrain, the ventral spinal card and the 
endocrine pancreas (Walther and Gruss, 1991). Homozygous 
mutant mice died at E6 to E8 before somite formation. Pax6 
heterozygote mice have a small body size (Theiler et al., 1978). 
A Pax6-homozygous human fetus with aniridia showed an 
absence of nasal bones and defects in parietal bones at ne-
cropsy (Hodgson and Saunders, 1980). However, the role of 
Pax6 in bone has never been studied. Therefore, we hypothe-
sized that Pax6 might play an important role in bone develop-
ment. 
In this paper, we showed that compared with the expression 
of Pax6 in cultured primary calvarial cells or established MC3T3- 
E1 preosteoblast cells, Pax6 was exclusively expressed in 
MLOY4 osteocyte-like cells (Fig. 1A). Two major isoforms of 
endogenous Pax6 [Pax6(-5a) and Pax6(+5a)] were detected at 
the mRNA level in bone cells (Fig. 1B). However, we found that 
Pax6(-5a) was the major Pax6 protein expressed in bone (Fig. 
1D). Pax6 was expressed exclusively in the calvaria and long 
bone tissues at E16 and E18 (Fig. 2). Pax6 has been reported 
to be essential for the proliferation and the pluripotency of reti-
nal progenitors (Hsieh and Yang, 2009). The proliferation and 
apoptosis of human retinoblastoma cells are regulated by Pax6 
(Bai et al., 2011). To evaluate the role of Pax6 in bone, we 
overexpressed and knocked down Pax6. In our study, neither 
knockdown nor overexpression of Pax6 exerted any effects on 
the proliferation or survival of MLOY4 cells (Figs. 3H-3K). Addi-
tionally, we observed that the knockdown of Pax6 decreased 
Fig. 5. Effect of Pax6 on Wnt signaling. (A)
MLOY4 cells were treated with Wnt-3a
conditioned media (100 µl/well), and the
effect on Pax6 and Sost mRNA expression
was measured at different time points with
RT-PCR. (B) MLOY4 cells were transfec-
ted with the indicated combinations of the
Super TOPFlash reporter DNA and Pax6
expression plasmids. After 48 h, the rela-
tive luciferase activity was measured. (C)
Schematic representation of the role of
Pax6 in inhibiting Wnt signaling through
Sost. *Indicates a p-value ≤ 0.05 relative
to the control. 
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the expression of Sost mRNA, which is a late osteocyte marker 
gene, and increased the expression of E11 and DMP1 (Figs. 
3A-3C). After transient transfection with Pax6(+5a) or Pax6(-5a) 
DNA, the expression of Sost was significantly increased (Figs. 
3D and 3E). The induction of Sost expression by Pax6 was 
further supported by the observation of enhanced luciferase 
reporter activity flanked by the 1,811 bp promoter region of the 
Sost gene after overexpression of each isoform of Pax6 (Fig. 
4D). In other studies, Pax6 was found to play an important role 
in lens fiber cell and neuronal cell differentiation (Gotz et al., 
1998; Shaham et al., 2009). In this study, we observed that the 
gradual increase of Pax6 mRNA during the differentiation of 
pre-osteoblast cells into mature osteoblasts (Figs. 1E and 1F). 
All these data suggest that Pax6 might play an important role in 
the differentiation of osteoblasts and osteocytes. 
In chicken telencephalic development, Wnt-3a induced the 
expression of the dorsal markers Pax6 and Ngn2 (Gunhaga et 
al., 2003). Moreover, Pax6 was shown to play an important role 
in lens morphogenesis through the inhibition of canonical 
Wnt/β-catenin signaling in the lens surface ectoderm (Machon 
et al., 2010). In our study, we also observed the induction of 
Pax6 expression in MLOY4 osteocyte-like cells after treatment 
with Wnt-3a (Fig. 5A). In addition, Wnt-3a/β-catenin reporter 
activity was significantly reduced by the overexpression of both 
Pax6(+5a) and Pax6(-5a) along with the co-transfection of the 
S-Top reporter vector in osteocyte-like MLOY4 cells (Fig. 5B). 
After transient transfection with Pax6(-5a) or Pax6(+5a) DNA, 
the expression of Sost increased significantly (Figs. 3D and 3E). 
Additionally, our in silico analysis showed that mouse and hu-
man Sost promoters exhibited a conserved, putative Pax6-
binding element (GGGAGTGCCAG) at the 2 kb upstream re-
gion of the Sost promoter. Overexpression of Pax6(+5a) or 
Pax6(-5a) along with pGL3-Sost promoter (wt) and pGL3-Sost 
promoter (mut) DNA revealed that mutant promoter activity was 
significantly lower than wild type promoter activity in the pres-
ence of both isoforms of Pax6 (Fig. 4D). All of these findings 
suggested that Pax6 inhibits canonical Wnt signaling through 
the stimulation of Sost by binding to its promoter. Canonical 
Wnt signaling has been shown to stimulate osteoblast differen-
tiation and inhibit the terminal differentiation of mature osteo-
blasts and apoptosis (Manolagas, 2000). In the present study, 
knockdown of Pax6 increased the expression of E11 and DMP1, 
and decreased the expression of Sost. In addition, Pax6 ex-
pression was increased according to further differentiation of 
osteoblasts. Therefore, we speculated that Pax6 may be an 
important transcription factor in stimulating further differentiation 
of mature osteoblasts to osteocytes. The potential role of Pax6 
is schematically represented in Fig. 5C. 
In conclusion, we showed that Pax6 is expressed in the cal-
varia and long bones of adult mice and osteocyte-like MLOY4 
cells. By direct binding to the putative Pax6 binding sequence 
of the Sost promoter region, Pax6 suppressed the canonical 
Wnt signaling pathway. Further exploration of phenotype in 
osteocyte-specific Pax6 knockout mice could provide more 
definitive evidence of the role of Pax6 in differentiation of ma-
ture osteoblasts to osteocytes.  
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